Adial Pharmaceuticals Stock Performance
| ADIL Stock | USD 2.85 0.18 5.94% |
The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Adial Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Adial Pharmaceuticals is expected to be smaller as well. At this point, Adial Pharmaceuticals has a negative expected return of -1.6%. Please make sure to confirm Adial Pharmaceuticals' skewness, and the relationship between the total risk alpha and rate of daily change , to decide if Adial Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Adial Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite conflicting performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in March 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return (5.94) | Five Day Return (21.92) | Year To Date Return (52.50) | Ten Year Return (99.89) | All Time Return (99.89) |
Last Split Factor 1:25 | Last Split Date 2026-02-06 |
1 | Will Adial Pharmaceuticals Inc. stock deliver strong dividend growth - July 2025 Outlook Free Technical Pattern Based Buy Signals - newser.com | 11/20/2025 |
2 | Adial Pharmaceuticals Secures 2.86M Through Warrant Agreement - TipRanks | 12/01/2025 |
3 | Litchfield Hills Research Forecasts ADIL FY2025 Earnings | 12/12/2025 |
4 | Adial Pharmaceuticals announces immediate resignation of board director - TipRanks | 01/06/2026 |
5 | Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045 - Chartmil... | 01/14/2026 |
6 | Thermo Fisher Scientific Inks Deal to Manufacture Adial Pharmaceuticals ADO4 - MSN | 01/23/2026 |
7 | Adial Pharmaceuticals announces 1-for-25 reverse stock split shares down | 02/03/2026 |
8 | Why Is Adial Pharmaceuticals Stock Down Today - TipRanks | 02/05/2026 |
Adial Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 813.00 in Adial Pharmaceuticals on November 14, 2025 and sell it today you would lose (528.00) from holding Adial Pharmaceuticals or give up 64.94% of portfolio value over 90 days. Adial Pharmaceuticals is currently does not generate positive expected returns and assumes 4.9242% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Adial, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adial Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Adial Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.85 | 90 days | 2.85 | close to 99 |
Based on a normal probability distribution, the odds of Adial Pharmaceuticals to move above the current price in 90 days from now is close to 99 (This Adial Pharmaceuticals probability density function shows the probability of Adial Stock to fall within a particular range of prices over 90 days) .
Adial Pharmaceuticals Price Density |
| Price |
Predictive Modules for Adial Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Adial Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Adial Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Adial Pharmaceuticals is not an exception. The market had few large corrections towards the Adial Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Adial Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Adial Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.54 | |
β | Beta against Dow Jones | 0.75 | |
σ | Overall volatility | 1.43 | |
Ir | Information ratio | -0.33 |
Adial Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Adial Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Adial Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Adial Pharmaceuticals generated a negative expected return over the last 90 days | |
| Adial Pharmaceuticals has high historical volatility and very poor performance | |
| Adial Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (13.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Adial Pharmaceuticals currently holds about 9.16 M in cash with (6.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Adial Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Why Is Adial Pharmaceuticals Stock Down Today - TipRanks |
Adial Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Adial Stock often depends not only on the future outlook of the current and potential Adial Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Adial Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 743.5 K | |
| Cash And Short Term Investments | 3.8 M |
Adial Pharmaceuticals Fundamentals Growth
Adial Stock prices reflect investors' perceptions of the future prospects and financial health of Adial Pharmaceuticals, and Adial Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adial Stock performance.
| Return On Equity | -1.55 | ||||
| Return On Asset | -0.79 | ||||
| Current Valuation | (1.21 M) | ||||
| Shares Outstanding | 1.11 M | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 0.75 X | ||||
| EBITDA | (8.28 M) | ||||
| Net Income | (13.2 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 975.86 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 4.72 X | ||||
| Cash Flow From Operations | (6.92 M) | ||||
| Earnings Per Share | (14.88) X | ||||
| Market Capitalization | 3.37 M | ||||
| Total Asset | 5.04 M | ||||
| Retained Earnings | (82 M) | ||||
| Working Capital | 3.08 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
About Adial Pharmaceuticals Performance
By examining Adial Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Adial Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Adial Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.36) | (2.47) | |
| Return On Capital Employed | (2.34) | (2.46) | |
| Return On Assets | (2.35) | (2.47) | |
| Return On Equity | (3.73) | (3.92) |
Things to note about Adial Pharmaceuticals performance evaluation
Checking the ongoing alerts about Adial Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adial Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adial Pharmaceuticals generated a negative expected return over the last 90 days | |
| Adial Pharmaceuticals has high historical volatility and very poor performance | |
| Adial Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (13.2 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Adial Pharmaceuticals currently holds about 9.16 M in cash with (6.92 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Adial Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Why Is Adial Pharmaceuticals Stock Down Today - TipRanks |
- Analyzing Adial Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adial Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Adial Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adial Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adial Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adial Pharmaceuticals' stock. These opinions can provide insight into Adial Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adial Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Adial Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Adial Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Adial's balance sheet. Smart investors calculate Adial Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Adial Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Adial Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Adial Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.